Lyra Therapeutics

Compare

371 Followers

LYRA Stock Chart & Stats

$5.52

>-$0.01(-3.42%)

At close: Jan 08 4:00 PM EST

$5.52

>-$0.01(-3.42%)

Day’s Range― - ―

52-Week Range$3.81 - $37.50

Previous CloseN/A

Volume832.93K

Average Volume (3M)39.06K

Market Cap

$9.58M

Enterprise Value$14.78M

Total Cash (Recent Filing)$29.78M

Total Debt (Recent Filing)$32.48M

Price to Earnings (P/E)―

Beta2.32

Next Earnings

Nov 11, 2025

EPS Estimate

-5.26

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.51

Shares Outstanding1,644,454

10 Day Avg. Volume26,240

30 Day Avg. Volume39,064

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.54

Enterprise Value/Revenue19.19

Enterprise Value/Gross Profit25.93

Enterprise Value/Ebitda-0.42

Forecast

1Y Price Target

$16.00

Price Target Upside189.86% Upside

Rating ConsensusHold

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe ENLIGHTEN 2 study met its primary and key secondary endpoints, renewing hope for LYR-210.

Market OpportunityIf the pursuit of LYR-210 FDA approval focuses on the CRSsNP patient population, it targets roughly 70% of CRS patients, which represents a significant portion of the market.

Regulatory ProgressFDA agreed to the use of a single primary endpoint of change from baseline in the 3 cardinal symptoms score, which simplifies the study requirements.

Bears Say

Funding ChallengesManagement has indicated that the potential to start the trial is pending additional funding, which could delay progress.

Strategic HurdlesThe greatest strategic hurdle for LYRA is reconciling the discrepancy between the positive ENLIGHTEN-2 trial and the negative ENLIGHTEN-1 trial.

Lyra Therapeutics News

Lyra Therapeutics announces clinical plan for LYR-210

Lyra Therapeutics (LYRA) announced the Company’s clinical plan and upcoming oral presentation of results from the positive Phase...

25d ago

LYRA

Lyra Therapeutics Posts Corporate Presentation on LYR-210

Lyra Therapeutics ( ($LYRA) ) has provided an update. On September 4, 2025, Lyra Therapeutics announced the posting...

2M ago

LYRA

Lyra Therapeutics Receives Nasdaq Deficiency Letter

An update from Lyra Therapeutics ( ($LYRA) ) is now available. On August 20, 2025, Lyra Therapeutics received...

2M ago

LYRA

Cautious Hold Rating on Lyra Therapeutics Amid Uncertainty in LYR-210’s Development and Approval Prospects

Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Hold rating on Lyra Therapeutics. The associated price target...

3M ago

LYRA

Lyra Therapeutics Faces Manufacturing and Staffing Challenges Amid LYR-210 Production Shift

Lyra Therapeutics, Inc. (LYRA) has disclosed a new risk, in the Manufacturing category. Lyra Therapeutics, Inc. faces significant...

3M ago

LYRA

Lyra Therapeutics Reports Q2 2025 Financial Results

Lyra Therapeutics, Inc. ( ($LYRA) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

LYRA

Lyra Therapeutics reports Q2 EPS ($5.51), consensus ($4.78)

Reports Q2 revenue $183,000, consensus $181,250. “The positive results from our ENLIGHTEN 2 trial have enabled us to...

3M ago

LYRA

Is LYRA a Buy, Before Earnings?

Lyra Therapeutics, Inc. (LYRA) is scheduled to report 2nd quarter earnings on 08/12/2025. Regarding Q2 estimates, Wall Street...

3M ago

LYRA

Lyra Therapeutics Announces Leadership Changes in August 2025

Lyra Therapeutics ( ($LYRA) ) has provided an update. On August 1, 2025, Lyra Therapeutics announced the immediate...

3M ago

LYRA

Lyra Therapeutics files to sell 846,744 shares of common stock for holders

17:16 EDT Lyra Therapeutics (LYRA) files to sell 846,744 shares of common stock for holders Published first on...

3M ago

LYRA

Lyra Therapeutics Secures $4.3M in Direct Offering

Lyra Therapeutics ( ($LYRA) ) just unveiled an update. On June 26, 2025, Lyra Therapeutics entered into a...

4M ago

LYRA

Lyra Therapeutics Regains Nasdaq Compliance in June 2025

An announcement from Lyra Therapeutics ( ($LYRA) ) is now available. On June 13, 2025, Lyra Therapeutics, Inc....

4M ago

LYRA

Lyra Therapeutics target adjusted to $16 from $2 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Lyra Therapeutics (LYRA) to $16 from $2 and keeps a...

5M ago

LYRA

Lyra Therapeutics Unveils Strategic Plans for LYR-210

Lyra Therapeutics ( ($LYRA) ) has provided an announcement. On June 9, 2025, Lyra Therapeutics announced the posting...

5M ago

LYRA

LYRA FAQ

What was Lyra Therapeutics’s price range in the past 12 months?

Lyra Therapeutics lowest stock price was $3.81 and its highest was $37.50 in the past 12 months.

What is Lyra Therapeutics’s market cap?

Lyra Therapeutics’s market cap is $9.58M.

When is Lyra Therapeutics’s upcoming earnings report date?

Lyra Therapeutics’s upcoming earnings report date is Nov 11, 2025 which is in 11 days.

How were Lyra Therapeutics’s earnings last quarter?

Lyra Therapeutics released its earnings results on Aug 12, 2025. The company reported -$5.51 earnings per share for the quarter, beating the consensus estimate of -$5.527 by $0.017.

Is Lyra Therapeutics overvalued?

According to Wall Street analysts Lyra Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Lyra Therapeutics pay dividends?

Lyra Therapeutics does not currently pay dividends.

What is Lyra Therapeutics’s EPS estimate?

Lyra Therapeutics’s EPS estimate is -5.26.

How many shares outstanding does Lyra Therapeutics have?

Lyra Therapeutics has 1,644,454 shares outstanding.

What happened to Lyra Therapeutics’s price movement after its last earnings report?

Lyra Therapeutics reported an EPS of -$5.51 in its last earnings report, beating expectations of -$5.527. Following the earnings report the stock price went up 8%.

Which hedge fund is a major shareholder of Lyra Therapeutics?

Currently, no hedge funds are holding shares in LYRA

Company Description

Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on transforming the treatment of chronic respiratory diseases through innovative drug delivery solutions. The company specializes in developing therapies for patients suffering from conditions such as chronic rhinosinusitis and other nasal and sinus disorders using its proprietary LYR-210 and LYR-220 product candidates, which aim to provide sustained release of therapeutic agents directly to the affected areas.

Lyra Therapeutics (LYRA) Earnings & Revenues

Historic Earnings Reports

LYRA Stock 12 Month Forecast

Average Price Target

$16.00

▲(189.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","263":"$263","68.75":"$68.8","133.5":"$133.5","198.25":"$198.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,68.75,133.5,198.25,263],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.57,7.295384615384616,8.02076923076923,8.746153846153847,9.471538461538461,10.196923076923078,10.922307692307694,11.647692307692308,12.373076923076923,13.098461538461539,13.823846153846155,14.54923076923077,15.274615384615386,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.57,7.295384615384616,8.02076923076923,8.746153846153847,9.471538461538461,10.196923076923078,10.922307692307694,11.647692307692308,12.373076923076923,13.098461538461539,13.823846153846155,14.54923076923077,15.274615384615386,{"y":16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.57,7.295384615384616,8.02076923076923,8.746153846153847,9.471538461538461,10.196923076923078,10.922307692307694,11.647692307692308,12.373076923076923,13.098461538461539,13.823846153846155,14.54923076923077,15.274615384615386,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":262.5,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.94,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.32,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.7,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.58,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.25,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.58,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.57,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >